We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
- Authors
Samaraweera, Amal P. R.; Cohen, Stuart N.; Akay, Ela M.; Evangelou, Nikos
- Abstract
Background: Fingolimod was the first oral disease-modifying treatment for relapsing–remitting multiple sclerosis. It has previously been associated with the development of lymphoma. Objective: To describe a case of lymphomatoid papulosis, a CD30+ cutaneous lymphoproliferative disorder, in a patient taking fingolimod. Methods: Case study. Results: Our patient developed lymphomatoid papulosis 2 months after starting fingolimod. Histology confirmed the diagnosis. The drug was withdrawn. Resolution began only 2 days later. Conclusions: Lymphomatoid papulosis is a benign subtype of cutaneous T-cell lymphoma, but up to 20% of cases can transform to a malignant course. Patients on fingolimod and physicians caring for them should be mindful of the need to monitor the skin.
- Subjects
LYMPHOPROLIFERATIVE disorders; IMMUNOLOGICAL deficiency syndromes; CELL proliferation; MULTIPLE sclerosis; FINGOLIMOD; PATIENTS
- Publication
Multiple Sclerosis Journal, 2016, Vol 22, Issue 1, p122
- ISSN
1352-4585
- Publication type
Article
- DOI
10.1177/1352458515597568